Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $5.89 USD
Change Today +0.13 / 2.26%
Volume 954.6K
As of 5:20 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

arrowhead research corp (ARWR) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/24/15 - $9.36
52 Week Low
08/24/15 - $4.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

arrowhead research corp (ARWR) Related Businessweek News

No Related Businessweek News Found

arrowhead research corp (ARWR) Details

Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its platform technology include Dynamic Polyconjugate platform, an RNAi delivery system that addresses multiple organ systems and cell types. The company is also involved in the development of Adipotide, which is in phase I clinical trial for the treatment of obesity and metabolic disorders; and CRLX-101 that is in phase II clinical trial to treat various cancer types, including relapsed renal cell carcinoma, relapsed ovarian cancer, and non-metastatic rectal cancer. It has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-drug conjugates. The company was formerly known as InterActive Group, Inc. Arrowhead Research Corporation was incorporated in 1989 and is headquartered in Pasadena, California.

81 Employees
Last Reported Date: 11/25/14
Founded in 1989

arrowhead research corp (ARWR) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $543.6K
Chief Financial Officer
Total Annual Compensation: $293.4K
Chief Operating Officer
Total Annual Compensation: $384.2K
Vice President of Strategy & Program Manageme...
Total Annual Compensation: $222.8K
Chief Scientific Officer
Total Annual Compensation: $226.4K
Compensation as of Fiscal Year 2014.

arrowhead research corp (ARWR) Key Developments

Arrowhead Research Corporation Announces Findings from the Heparc-2001 Phase 2a Clinical Study of ARC-520

Arrowhead Research Corporation announced top-line findings from the Heparc-2001 Phase 2a clinical study of ARC-520, its candidate for the treatment of chronic hepatitis B infection. Additionally, the company announced findings from a study of 9 chimpanzees that have been treated monthly with ARC-520 for between 6 and 11 months with a background therapy of nucleotide/nucleoside analog inhibitors (NUCs) tenofovir and/or entecavir. Key findings: Arrowhead's proprietary DPC platform can effectively and consistently knock down target genes in humans HBV E-antigen positive (HBeAg-positive) patients on a background of chronic entecavir receiving a 4 mg/kg single-dose of ARC-520 showed a mean maximal 92% (1.2 log) reduction in circulating HBeAg and a best reduction of 98% (1.7 log). Similar mean maximal reductions were also demonstrated in HBV core-related antigen (HBcrAg) from both HBeAg-negative and -positive patients. ARC-520 is designed to silence all gene products expressed by HBV cccDNA, so this data suggests that it may be substantially disrupting additional viral functions. ARC-520 achieves significant HBV s-Antigen (HBsAg) reductions in humans, particularly in treatment naive, HBeAg-positive patients. In a cohort of NUC-naive, HBeAg-positive patients, best peak HBsAg reduction has been 99% (1.9 log) and the mean maximum HBsAg reduction has been 1.05 log through 15 days post ARC-520 treatment. This open-label cohort is fully enrolled; data collection is ongoing and will be continued through Day 85 post ARC-520 treatment. These reductions are substantially higher than results from NUC treatment-experienced cohorts. Arrowhead identifies a large target HBV population for ARC-520 and describes a new paradigm for the HBV lifecycle. Arrowhead's long-term chimp study and findings from the clinical study suggest that HBV cccDNA decreases during the HBV lifecycle, especially with the transition from HBeAg-positive to -negative. HBV DNA integrated into host DNA appears to maintain significant HBsAg production as cccDNA declines. This process is accelerated with NUC treatment. ARC-520 specifically targets cccDNA, and NUC-naive HBeAg-positive patients are expected to be richest in cccDNA. It is estimated in the U.S. that 95% of people chronically infected with HBV are currently NUC-naive and at least 50% of them are likely to be HBeAg-positive. While it is unknown what impact ARC-520's broad based effects on HBV biology will have on the sero-clearance process in any of the HBV subgroups, the effect on HBsAg in NUC-naive HBeAg-positive patients makes this group especially attractive to study and a key focus for multi-dose studies going forward. ARC-520 induces deep HBsAg reduction in chronically HBV infected chimps and 1 of 4 HBeAg-positive chimps demonstrated signs of immune reactivation during therapy 9 chimps were first suppressed with NUCs and then treated with 6 - 11 monthly doses of ARC-520. 4 HBeAg-positive chimps demonstrated 99% (2 log) mean peak reduction in HBsAg, and 1 of the 4 experienced signs of immune reactivation during therapy; 4 HBeAg-negative chimps demonstrated 81% (0.7 log) mean peak reduction in HBsAg; and 1 chimp transitioning from HBeAg-positive to HBeAg-negative demonstrated peak HBsAg reduction of 87% (0.9 log). ARC-520 has been well tolerated 84 humans have received ARC-520 and to date no adverse events have been rated as serious or severe, no discontinuations have occurred due to an adverse event, and no laboratory results have indicated any end organ toxicity. Additionally, 9 chimps received 6-11 monthly doses of ARC-520 and no safety signals were detected in any chimp. Arrowhead expands its HBV portfolio by nominating an additional clinical candidate that is complementary to ARC-520. ARC-520 will continue development including focus on the significant market of e-antigen positive treatment-naive chronic HBV patients. ARC-521 is being developed to target cccDNA and also, integrated DNA, which appears to be a more significant producer of HBsAg in patients who have been treated with NUCs or who are e-antigen negative. In HBeAg-negative chimps predicted to have higher levels of integrated DNA, administration of the integrant-targeted siRNA in ARC-521 led to 99% (2 logs) of additional HBsAg reduction. The company expects to file an IND or equivalent for ARC-521 by mid-2016.

Arrowhead Research Corporation Nominates ARC-HIF2 as First RNAi Therapeutic Candidate Using Extrahepatic DPC™ Delivery System

Arrowhead Research Corporation announced that it has nominated ARC-HIF2 as its first therapeutic candidate delivered using a new Dynamic Polyconjugate™ (DPC™) designed to target tissues outside of the liver. Arrowhead believes that ARC-HIF2, which uses RNA interference to silence transcription factor hypoxia-inducible factor 2a (HIF-2a), is a promising new candidate for the treatment of clear cell renal cell carcinoma (ccRCC). The company will present preclinical data at the European Cancer Congress 2015 (ECC2015) in Vienna on September 27. In a poster titled 'HIF-2a targeting with a novel RNAi delivery platform as therapy for renal cell carcinoma,' (abstract #353), Arrowhead scientists will show data suggesting that HIF-2a inhibition through RNA interference may significantly impact late stage ccRCC progression. The company is in the process of manufacturing scale up to allow for initiation of IND-enabling studies. Timing for anticipated regulatory submission will be announced in the future. ARC-HIF2 is designed to inhibit the production of HIF-2a, which has been linked to tumor progression and metastasis in ccRCC. ARC-HIF2 employs a novel extrahepatic-targeted DPC™ that comprises a membrane active polymer to promote RNAi trigger endosomal release, an active ligand that targets the DPC™ to tumor cells, reversible masking to prevent polymer activity prior to cellular uptake, and an RNAi trigger to HIF-2a conjugated directly to the DPC™. Using ARC-HIF2 in a preclinical ccRCC tumor model, mice treated with weekly injections led to greater than 80% knockdown of HIF-2a mRNA in tumors. Furthermore, tumors from treated mice exhibited statistically significant reductions in size and weight, extensive tumor cell death, reduction in the tumor-expressed VEGF-A biomarker, and destruction of the blood vessels feeding the tumors. Therapies for metastatic ccRCC including agents that target the VEGF/VEGFR or mTor signaling pathways, which are validated cancer targets, have become the standard-of-care and have improved patient outcomes. However, since emergence of resistance to these agents is common, novel therapies targeting alternative pathways are needed for patients with resistant tumors. Arrowhead believes that HIF2a is an attractive target for intervention because over 90% of ccRCC tumors express a mutant form of the Von Hippel-Landau protein that is unable to degrade HIF-2a, leading to its accumulation during tumor hypoxia and promoting tumor growth.

Arrowhead Research Corp. Presents at Jefferies 2015 Hepatitis B Summit, Aug-06-2015

Arrowhead Research Corp. Presents at Jefferies 2015 Hepatitis B Summit, Aug-06-2015 . Venue: Boston Harbor Hotel, North Atlantic Room, Boston, Massachusetts, United States. Speakers: Bruce D. Given, Chief Operating Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARWR:US $5.89 USD +0.13

ARWR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARWR.
View Industry Companies

Industry Analysis


Industry Average

Valuation ARWR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 897.1x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 607.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARROWHEAD RESEARCH CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at